Publications by authors named "Lina Asmar"

68Publications

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.

Authors:
Devchand Paul Svetislava J Vukelja Frankie Ann Holmes Joanne L Blum Kristi J McIntyre Deborah L Lindquist Cynthia R Osborne Ines J Sanchez Jerome H Goldschmidt Yunfei Wang Lina Asmar Lewis Strauss Joyce O'Shaughnessy

NPJ Breast Cancer 2019 28;5:36. Epub 2019 Oct 28.

1US Oncology Research, Inc., 10101 Woodloch Forest Dr., The Woodlands, TX 77380 USA.

View Article and Find Full Text PDF
October 2019

Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.

Authors:
Frankie Ann Holmes Beth A Hellerstedt John E Pippen Svetislava J Vukelja Rufus P Collea Darren M Kocs Joanne L Blum Kristi J McIntyre Minal A Barve Barry D Brooks Cynthia R Osborne Yunfei Wang Lina Asmar Joyce O'Shaughnessy

Cancer Med 2018 06 26;7(6):2288-2298. Epub 2018 Mar 26.

US Oncology Research, McKesson Specialty Health, The Woodlands, Texas.

View Article and Find Full Text PDF
June 2018

Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.

Authors:
Cynthia Osborne Jagathi D Challagalla Charles F Eisenbeis Frankie Ann Holmes Marcus A Neubauer Nicholas W Koutrelakos Carlos A Taboada Sasha J Vukelja Sharon T Wilks Mary Ann Allison Praveen Reddy Scot Sedlacek Yunfei Wang Lina Asmar Joyce O'Shaughnessy

Clin Breast Cancer 2018 02 10;18(1):e89-e95. Epub 2017 Jul 10.

US Oncology Research, McKesson Specialty Health, The Woodlands, TX; Texas Oncology, Baylor-Sammons Cancer Center, Dallas, TX.

View Article and Find Full Text PDF
February 2018

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

Authors:
Joanne L Blum Patrick J Flynn Greg Yothers Lina Asmar Charles E Geyer Samuel A Jacobs Nicholas J Robert Judith O Hopkins Joyce A O'Shaughnessy Chau T Dang Henry Leonidas Gómez Louis Fehrenbacher Svetislava J Vukelja Alan P Lyss Devchand Paul Adam M Brufsky Jong-Hyeon Jeong Linda H Colangelo Sandra M Swain Eleftherios P Mamounas Stephen E Jones Norman Wolmark

J Clin Oncol 2017 Aug 11;35(23):2647-2655. Epub 2017 Apr 11.

Joanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.

View Article and Find Full Text PDF
August 2017

Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.

Authors:
Lea K Krekow Beth A Hellerstedt Rufus P Collea Steven Papish Shrinivas M Diggikar Regina Resta Svetislava J Vukelja Frankie Ann Holmes Praveen K Reddy Lina Asmar Yunfei Wang Patricia S Fox Susan R Peck Joyce O'Shaughnessy

J Clin Oncol 2016 05 16;34(14):1594-600. Epub 2016 Feb 16.

Lea K. Krekow, Beth A. Hellerstedt, Rufus P. Collea, Steven Papish, Shrinivas M. Diggikar, Regina Resta, Svetislava J. Vukelja, Frankie Ann Holmes, Lina Asmar, Yunfei Wang, Patricia S. Fox, and Joyce O'Shaughnessy, US Oncology Research; Susan R. Peck, McKesson Specialty Health, The Woodlands; Lea K. Krekow, Texas Oncology-The Breast Care Center of North Texas, Bedford; Beth A. Hellerstedt, Texas Oncology-Austin Central, Austin; Shrinivas M. Diggikar, Texas Oncology-Arlington South, Arlington; Svetislava J. Vukelja, Texas Oncology/Tyler Cancer Center, Tyler; Frankie Ann Holmes, Texas Oncology-Houston Memorial City, Houston; Praveen K. Reddy, Texas Oncology Midland Allison Cancer Center, Midland; Joyce O'Shaughnessy, Texas Oncology at Baylor-Charles A. Sammons Cancer Center, Dallas, TX; Rufus P. Collea, New York Oncology Hematology-Albany Medical Center, Albany; Regina Resta, New York Oncology Hematology, Troy, NY; and Steven Papish, Hematology-Oncology Associates of Northern New Jersey, Morristown, NJ.

View Article and Find Full Text PDF
May 2016

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices.

Authors:
Neelima Denduluri Debra A Patt Yunfei Wang Menaka Bhor Xiaoyan Li Anne M Favret Phuong Khanh Morrow Richard L Barron Lina Asmar Shanmugapriya Saravanan Yanli Li Jacob Garcia Gary H Lyman

J Natl Compr Canc Netw 2015 Nov;13(11):1383-93

From Virginia Cancer Specialists PC and The US Oncology Network, Arlington, Virginia; McKesson Specialty Health and The US Oncology Network, The Woodlands, Texas; Amgen Inc., Thousand Oaks, California; Virginia Cancer Specialists PC and The US Oncology Network, Fairfax, Virginia; Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article and Find Full Text PDF
November 2015

Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.

Authors:
John W Smith Svetislava Vukelja Amy Rabe Nicole Wentworth-Hartung Nicholas Koutrelakos Spencer H Shao Thomas Whittaker Yunfei Wang Lina Asmar Diane Opatt McDowell Pralay Mukhopadhyay Joyce O'Shaughnessy

Breast Cancer Res Treat 2013 Nov 29;142(2):381-8. Epub 2013 Oct 29.

Compass Oncology, 5050 NE Hoyt Street, Suite 256, Portland, OR, 97213, USA,

View Article and Find Full Text PDF
November 2013

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

Authors:
Stephen E Jones Rufus Collea Devchand Paul Scot Sedlacek Anne M Favret Ira Gore Deborah L Lindquist Frankie Ann Holmes Mary Ann K Allison Barry D Brooks Raul M Portillo Svetislava J Vukelja Michael S Steinberg Christopher Stokoe Maria W Crockett Yunfei Wang Lina Asmar Nicholas J Robert Joyce O'Shaughnessy

Lancet Oncol 2013 Oct 3;14(11):1121-1128. Epub 2013 Sep 3.

US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA; Texas Oncology, Baylor-Sammons Cancer Center, Dallas, TX, USA.

View Article and Find Full Text PDF
October 2013

Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial.

Authors:
Craig Reynolds Alexander I Spira Larry Gluck Suzanne J Bradie-Muller Suzanne E Mueller Feng Zhan Kristi A Boehm Lina Asmar

Invest New Drugs 2013 Oct 13;31(5):1330-8. Epub 2013 Jun 13.

Ocala Oncology, Ocala, FL, USA,

View Article and Find Full Text PDF
October 2013

Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.

Authors:
Donald Richards Darren M Kocs Alexander I Spira A David McCollum Sami Diab Lanny I Hecker Allen Cohn Feng Zhan Lina Asmar

Eur J Cancer 2013 Sep 5;49(13):2823-31. Epub 2013 Jun 5.

US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA.

View Article and Find Full Text PDF
September 2013

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

Authors:
Matthew D Galsky Noah M Hahn Thomas Powles Beth A Hellerstedt Seth P Lerner Thomas A Gardner Menggang Yu Mark O'Rourke Nicholas J Vogelzang Darren Kocs Scott A McKenney Anton M Melnyk Thomas E Hutson Mary Rauch Yunfei Wang Lina Asmar Guru Sonpavde

Clin Genitourin Cancer 2013 Jun 8;11(2):175-81. Epub 2012 Dec 8.

US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA.

View Article and Find Full Text PDF
June 2013

Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial.

Authors:
Kui Shen Yuan Qi Nan Song Chunqiao Tian Shara D Rice Michael J Gabrin Stacey L Brower William Fraser Symmans Joyce A O'Shaughnessy Frankie A Holmes Lina Asmar Lajos Pusztai

BMC Med Genomics 2012 Nov 16;5:51. Epub 2012 Nov 16.

Department of Product Development, Precision Therapeutics, Inc, 2516 Jane Street, Pittsburgh, PA 15203, USA.

View Article and Find Full Text PDF
November 2012

Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.

Authors:
Mark T Fleming Guru Sonpavde Michael Kolodziej Sanjay Awasthi Thomas E Hutson Danko Martincic Ashutosh Rastogi Steven R Rousey Ralph E Weinstein Matthew D Galsky William R Berry Yunfei Wang Kristi A Boehm Lina Asmar Mary A Rauch Tomasz M Beer

Clin Genitourin Cancer 2012 Mar;10(1):6-14

US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA.

View Article and Find Full Text PDF
March 2012

A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer.

Authors:
Dennis L Carter David Garfield James Hathorn Richard Mundis Kristi A Boehm Des Ilegbodu Lina Asmar Craig Reynolds

Clin Lung Cancer 2012 May 3;13(3):205-13. Epub 2011 Dec 3.

US Oncology Research, LLC, The Woodlands, TX, USA.

View Article and Find Full Text PDF
May 2012

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

Authors:
Leonard Saltz Suprith Badarinath Shaker Dakhil Bryan Bienvenu W Graydon Harker George Birchfield Laurence K Tokaz David Barrera Paul R Conkling Mark A O'Rourke Donald A Richards Diane Reidy David Solit Efsevia Vakiani Marinella Capanu Amy Scales Feng Zhan Kristi A Boehm Lina Asmar Allen Cohn

Clin Colorectal Cancer 2012 Jun 4;11(2):101-11. Epub 2011 Nov 4.

Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.

View Article and Find Full Text PDF
June 2012

A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.

Authors:
Craig Reynolds Nicholas Di Bella Roger M Lyons William Hyman Donald A Richards Gerald J Robbins Mark Vellek Kristi A Boehm Feng Zhan Lina Asmar

Invest New Drugs 2012 Jun 16;30(3):1232-40. Epub 2011 Sep 16.

US Oncology Research, LLC., The Woodlands, TX, USA.

View Article and Find Full Text PDF
June 2012

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.

Authors:
Cornelis J H van de Velde Daniel Rea Caroline Seynaeve Hein Putter Annette Hasenburg Jean-Michel Vannetzel Robert Paridaens Christos Markopoulos Yasuo Hozumi Elysee T M Hille Dirk G Kieback Lina Asmar Jan Smeets Johan W R Nortier Peyman Hadji John M S Bartlett Stephen E Jones

Lancet 2011 Jan;377(9762):321-31

Leiden University Medical Centre, Leiden, Netherlands.

View Article and Find Full Text PDF
January 2011

A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.

Authors:
Charles H Weissman Craig H Reynolds Marcus A Neubauer Sharon Pritchard Svetlana Kobina Lina Asmar

J Thorac Oncol 2011 Feb;6(2):358-64

US Oncology Research, Inc., Houston, Texas, USA.

View Article and Find Full Text PDF
February 2011

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.

Authors:
Nicholas J Robert Paul R Conkling Mark A O'Rourke Paul R Kuefler Kristi J McIntyre Feng Zhan Lina Asmar Yanping Wang Oluwatoyin O Shonukan Joyce A O'Shaughnessy

Breast Cancer Res Treat 2011 Feb 25;126(1):101-8. Epub 2010 Dec 25.

US Oncology Research, Inc., The Woodlands, TX, USA,

View Article and Find Full Text PDF
February 2011

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.

Authors:
Peyman Hadji Lina Asmar Johanna G H van Nes Thomas Menschik Annette Hasenburg Joachim Kuck Johan W R Nortier Cornelis J H van de Velde Stephen E Jones May Ziller

J Cancer Res Clin Oncol 2011 Jun 18;137(6):1015-25. Epub 2010 Dec 18.

Department of Gynaecological Endocrinology, Reproductive Medicine and Osteoporosis, Philipps-University of Marburg, Baldingerstrasse, 35033 Marburg, Germany.

View Article and Find Full Text PDF
June 2011

Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer.

Authors:
Mark A Socinski Robert N Raju Thomas Stinchcombe Darren M Kocs Linda S Couch David Barrera Steven R Rousey Janak K Choksi Robert Jotte Debra A Patt Phillip O Periman Howard R Schlossberg Charles H Weissman Yunfei Wang Lina Asmar Sharon Pritchard Jane Bromund Guangbin Peng Joseph Treat Coleman K Obasaju

J Thorac Oncol 2010 Dec;5(12):1963-9

Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599-7305, USA.

View Article and Find Full Text PDF
December 2010

A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.

Authors:
Robert M Rifkin Andrew Greenspan John F Schwerkoske Romeo A Mandanas Joe J Stephenson George T Kannarkat Feng Zhan Kristi A Boehm Lina Asmar Roy Beveridge

Invest New Drugs 2012 Apr 12;30(2):714-22. Epub 2010 Oct 12.

US Oncology Research, Inc, The Woodlands, TX, USA.

View Article and Find Full Text PDF
April 2012

Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.

Authors:
Robert Rifkin Gary Spitzer Gregory Orloff Romeo Mandanas Dean McGaughey Feng Zhan Kristi A Boehm Lina Asmar Roy Beveridge

Clin Lymphoma Myeloma Leuk 2010 Jun;10(3):186-91

Blood and Marrow Transplant Network, US Oncology Research, Inc, The Woodlands, TX, USA.

View Article and Find Full Text PDF
June 2010

Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.

Authors:
David Loesch F Anthony Greco Neil N Senzer Howard A Burris John D Hainsworth Stephen Jones Svetislava J Vukelja John Sandbach Frankie Holmes Scot Sedlacek John Pippen Deborah Lindquist Kristi McIntyre Joanne L Blum Manuel R Modiano Kristi A Boehm Feng Zhan Lina Asmar Nicholas Robert

J Clin Oncol 2010 Jun 17;28(18):2958-65. Epub 2010 May 17.

US Oncology Research, The Woodlands, TX, USA.

View Article and Find Full Text PDF
June 2010

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.

Authors:
Nicholas Di Bella Raymond Taetle Kathryn Kolibaba Thomas Boyd Robert Raju David Barrera Ernest W Cochran Philip Y Dien Roger Lyons Peter J Schlegel Svetislava J Vukelja Julie Boston Kristi A Boehm Yunfei Wang Lina Asmar

Blood 2010 Jan 19;115(3):475-80. Epub 2009 Nov 19.

US Oncology Research Inc, The Woodlands, TX, USA.

View Article and Find Full Text PDF
January 2010

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.

Authors:
Guru Sonpavde Ana M Aparicio Feng Zhan Brittany North Robert Delaune Lawrence E Garbo Steven R Rousey Ralph E Weinstein Lianchun Xiao Kristi A Boehm Lina Asmar Mark T Fleming Matthew D Galsky William R Berry Daniel D Von Hoff

Urol Oncol 2011 Nov-Dec;29(6):682-9. Epub 2009 Dec 3.

US Oncology Research, Inc., The Woodlands, TX 77380, USA.

View Article and Find Full Text PDF
March 2012

Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.

Authors:
Craig Reynolds David Barrera Robert Jotte Alexander I Spira Charles Weissman Kristi A Boehm Sharon Pritchard Lina Asmar

J Thorac Oncol 2009 Dec;4(12):1537-43

US Oncology Research, Inc., The Woodlands, Texas, USA.

View Article and Find Full Text PDF
December 2009

Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.

Authors:
Craig Reynolds Coleman Obasaju Michael J Schell Xueli Li Zhong Zheng David Boulware John R Caton Linda C Demarco Mark A O'Rourke Gail Shaw Wright Kristi A Boehm Lina Asmar Jane Bromund Guangbin Peng Matthew J Monberg Gerold Bepler

J Clin Oncol 2009 Dec 2;27(34):5808-15. Epub 2009 Nov 2.

US Oncology, The Woodlands, TX, USA.

View Article and Find Full Text PDF
December 2009

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.

Authors:
Donald A Richards Paul R Kuefler Carlos Becerra Lalan S Wilfong Robert H Gersh Kristi A Boehm Feng Zhan Lina Asmar Scott P Myrand Rebecca R Hozak Luping Zhao John F Gill Brian P Mullaney Coleman K Obasaju Steven J Nicol

Invest New Drugs 2011 Feb 28;29(1):144-53. Epub 2009 Aug 28.

US Oncology Research, Inc., The Woodlands, TX, USA.

View Article and Find Full Text PDF
February 2011

Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.

Authors:
John W Smith Kristi J McIntyre Patrick V Acevedo Carlos A Encarnacion Karen L Tedesco Yunfei Wang Lina Asmar Joyce A O'Shaughnessy

Breast Cancer Res Treat 2009 Nov 21;118(2):361-7. Epub 2009 May 21.

US Oncology Research, Inc., The Woodlands, TX, USA.

View Article and Find Full Text PDF
November 2009

Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.

Authors:
Michael G Teneriello Paul C Tseng Mark Crozier Carlos Encarnacion Kenneth Hancock Mark J Messing Kristi A Boehm Alicia Williams Lina Asmar

J Clin Oncol 2009 Mar 17;27(9):1426-31. Epub 2009 Feb 17.

US Oncology Research, Houston, TX, USA.

View Article and Find Full Text PDF
March 2009

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

Authors:
Stephen Jones Frankie Ann Holmes Joyce O'Shaughnessy Joanne L Blum Svetislava J Vukelja Kristi J McIntyre John E Pippen James H Bordelon Robert L Kirby John Sandbach William J Hyman Donald A Richards Robert G Mennel Kristi A Boehm Wally G Meyer Lina Asmar Daniel Mackey Stefan Riedel Hyman Muss Michael A Savin

J Clin Oncol 2009 Mar 9;27(8):1177-83. Epub 2009 Feb 9.

US Oncology Research Inc, Texas Oncology PA, 3535 Worth St, 6th floor, Dallas, TX 75246, USA.

View Article and Find Full Text PDF
March 2009

The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.

Authors:
Stephen Jones Christopher Stokoe Mark Sborov Marcus Braun Sukumar Ethirajan Leila Kutteh John Pippen Mrugesh Patel Devchand Paul Joanne L Blum Frankie Ann Holmes Mark C Myron James Cantrell Nichole L Hartung Regan M Look Enrico Di Salle Jennifer C Davis Des Ilegbodu Lina Asmar

Clin Breast Cancer 2008 Dec;8(6):527-32

US Oncology Research, Inc., Houston, TX, USA.

View Article and Find Full Text PDF
December 2008

Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.

Authors:
Thomas Cartwright Paul Kuefler Allen Cohn William Hyman Maury Berger Donald Richards Svetislava Vukelja John E Nugent Robert L Ruxer Kristi A Boehm Lina Asmar

Clin Colorectal Cancer 2008 Nov;7(6):390-7

US Oncology, Houston, TX, USA.

View Article and Find Full Text PDF
November 2008

Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

Authors:
Guru Sonpavde Thomas E Hutson William R Berry Kristi A Boehm Lina Asmar

Clin Genitourin Cancer 2008 Sep;6(2):134-7

Texas Oncology and Baylor Sammons Cancer Center, Dallas, TX, USA.

View Article and Find Full Text PDF
September 2008

A randomized, multicenter, open-label comparison of the antiemetic efficacy of dolasetron versus ondansetron for the prevention of nausea and vomiting during high-dose myeloablative chemotherapy.

Authors:
Romeo A Mandanas Roy Beveridge Robert M Rifkin Hugh Wallace Andrew Greenspan Lina Asmar

Support Cancer Ther 2005 Jan;2(2):114-21

US Oncology Research, Inc., Houston, Texas.

View Article and Find Full Text PDF
January 2005

Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.

Authors:
David Loesch Lina Asmar Kristi McIntyre Lisa Doane Michael Monticelli Devchand Paul Svetislava Vukelja Mauro Orlando LaTrice G Vaughn Feng Zhan Kristi A Boehm Joyce A O'Shaughnessy

Clin Breast Cancer 2008 Apr;8(2):178-86

US Oncology Research, Inc, Houston, TX, USA.

View Article and Find Full Text PDF
April 2008

Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma.

Authors:
Dennis L Carter Lina Asmar David Barrera John Caracandas J Shaker Dakhil Dean McCracken Mark A O'Rourke Richard K Rosenberg Kristi A Boehm Des Ilegbodu Robert L Reid

Invest New Drugs 2008 Oct 13;26(5):473-81. Epub 2008 May 13.

US Oncology Research, Inc., Houston, TX, USA.

View Article and Find Full Text PDF
October 2008

A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma.

Authors:
Allen L Cohn J William Myers Steven Mamus Charles Deur Steven Nicol Karen Hood Muhammad M Khan Des Ilegbodu Lina Asmar

Invest New Drugs 2008 Aug 28;26(4):381-6. Epub 2008 Feb 28.

US Oncology Research, Inc., Houston, TX, USA.

View Article and Find Full Text PDF
August 2008

Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.

Authors:
Guru Sonpavde Ana Aparicio Israel Guttierez Kristi A Boehm Thomas E Hutson William R Berry Lina Asmar Daniel D von Hoff

Clin Genitourin Cancer 2007 Dec;5(7):457-9

US Oncology Research, Inc., 501 Medical Center Blvd, Webster, TX 77598, USA.

View Article and Find Full Text PDF
December 2007

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.

Authors:
Stephen E Jones James Cantrell Svetislava Vukelja John Pippen Joyce O'Shaughnessy Joanne L Blum Robert Brooks Nicole L Hartung Angel G Negron Donald A Richards Ragene Rivera Frankie Ann Holmes Sreeni Chittoor Thomas L Whittaker James H Bordelon Steven J Ketchel Jennifer C Davis Des Ilegbodu Jean Kochis Lina Asmar

J Clin Oncol 2007 Oct;25(30):4765-71

US Oncology Research Inc, Houston, TX, USA.

View Article and Find Full Text PDF
October 2007

Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.

Authors:
Joanne L Blum E Claire Dees Svetislava J Vukelja Mammo Amare David P Gill Richard T McMahon Des Ilegbodu Lina Asmar Joyce A O'Shaughnessy

Clin Breast Cancer 2007 Feb;7(6):465-70

US Oncology Research, Inc, Houston, TX, USA.

View Article and Find Full Text PDF
February 2007

Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic?

Authors:
William Berry Maha Elkordy Mark O'Rourke Myrna Khan Lina Asmar

Cancer Invest 2007 Feb;25(1):27-31

US Oncology Research, Inc., Houston, Texas, USA.

View Article and Find Full Text PDF
February 2007

Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.

Authors:
Sreeni Chittoor William Berry David Loesch Keith Logie John Fleagle Stephanie Mull Kristi A Boehm Feng Zhan Lina Asmar

Clin Genitourin Cancer 2006 Dec;5(3):212-8

US Oncology Research, Inc, Houston, TX, USA.

View Article and Find Full Text PDF
December 2006

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

Authors:
Stephen E Jones Michael A Savin Frankie Ann Holmes Joyce A O'Shaughnessy Joanne L Blum Svetislava Vukelja Kristi J McIntyre John E Pippen James H Bordelon Robert Kirby John Sandbach William J Hyman Pankaj Khandelwal Angel G Negron Donald A Richards Stephen P Anthony Robert G Mennel Kristi A Boehm Walter G Meyer Lina Asmar

J Clin Oncol 2006 Dec;24(34):5381-7

US Oncology Research, Inc, Texas Oncology, Dallas, TX 75246, USA.

View Article and Find Full Text PDF
December 2006

Phase II Trial of a Novel Paclitaxel Schedule As Single-Agent, First-Line Therapy for HER-2/neu-Negative Metastatic Breast Cancer: A Community-Based Study.

Authors:
David Loesch Nicholas Robert Stephen Jones Maha Elkordy Des Ilegbodu Lina Asmar

J Oncol Pract 2006 Nov;2(6):268-73

US Oncology Research Inc, Houston, TX.

View Article and Find Full Text PDF
November 2006

Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.

Authors:
Michael Kolodziej Marcus A Neubauer Steven R Rousey Robert E Pluenneke George Perrine Stephanie Mull Kristi A Boehm Des Ilegbodu Lina Asmar

Clin Genitourin Cancer 2006 Sep;5(2):155-61

US Oncology Research Inc, Houston, TX, USA.

View Article and Find Full Text PDF
September 2006

A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.

Authors:
William Berry David Friedland John Fleagle Don Jackson Des Ilegbodu Kristi A Boehm Lina Asmar

Clin Genitourin Cancer 2006 Sep;5(2):131-7

US Oncology, Inc, Houston, TX, USA.

View Article and Find Full Text PDF
September 2006

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.

Authors:
Joanne L Blum E Claire Dees Aparna Chacko Lisa Doane Sukumar Ethirajan Judith Hopkins Richard McMahon Suzan Merten Angel Negron Marcus Neubauer Des Ilegbodu Kristi A Boehm Lina Asmar Joyce A O'Shaughnessy

J Clin Oncol 2006 Sep 22;24(27):4384-90. Epub 2006 Aug 22.

US Oncology Research Inc, Houston, USA.

View Article and Find Full Text PDF
September 2006

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.

Authors:
Nicholas Robert Brian Leyland-Jones Lina Asmar Robert Belt Des Ilegbodu David Loesch Robert Raju Elizabeth Valentine Robert Sayre Melody Cobleigh Kathy Albain Cecelia McCullough Lea Fuchs Dennis Slamon

J Clin Oncol 2006 Jun;24(18):2786-92

US Oncology Research Inc, Houston, TX, USA.

View Article and Find Full Text PDF
June 2006

Results of a Phase II study of weekly docetaxel and carboplatin in Stage IIIB (with effusion) or Stage IV non-small cell lung cancer patients age

Authors:
Charles H Weissman John Sandbach Reginald Brooker Mark Vellek Deborah Lindquist Paul Conkling Des Ilegbodu Lina Asmar

Lung Cancer 2006 Jun 18;52(3):313-7. Epub 2006 Apr 18.

US Oncology Research, Inc., 12941 North Freeway, Suite 700, Houston, TX 77060, USA.

View Article and Find Full Text PDF
June 2006

Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.

Authors:
Joyce A O'Shaughnessy Robert Pluenneke Jack Sternberg Pankaj Khandelwal Des Ilegbodu Lina Asmar

Clin Breast Cancer 2006 Feb;6(6):505-10

US Oncology, Dallas, TX 75246, USA.

View Article and Find Full Text PDF
February 2006

Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.

Authors:
Thomas Cartwright Timothy Lopez Svetislava J Vukelja Carlos Encarnacion Kristi A Boehm Lina Asmar

Clin Colorectal Cancer 2005 May;5(1):50-6

US Oncology Research, Inc., Houston, TX, USA.

View Article and Find Full Text PDF
May 2005

Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.

Authors:
Marcus A Neubauer Craig H Reynolds Marcos G Joppert Thomas Whitaker Habib Ghaddar Thomas A Marsland Lina Asmar

Clin Lung Cancer 2005 Jan;6(4):245-9

US Oncology Research, Inc., Houston, TX, USA.

View Article and Find Full Text PDF
January 2005

An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma.

Authors:
Nicholas Di Bella Craig Reynolds David Faragher Joseph Muscato Kristi A Boehm Lina Asmar

Cancer 2005 Mar;103(5):978-84

US Oncology Research, Inc., Houston, Texas, USA .

View Article and Find Full Text PDF
March 2005

Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.

Authors:
Marcus A Neubauer David H Garfield Paul R Kuerfler Robert N Raju Deborah L Lindquist Edward W Soo Myrna Khan Kristi A Boehm Lina Asmar

Lung Cancer 2005 Jan;47(1):121-7

US Oncology, Inc., 12941 North Freeway, Suite 700, Houston, TX 77060, USA.

View Article and Find Full Text PDF
January 2005

Results of a Phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer.

Authors:
Marcus Neubauer Ralph Heaven Jairo Olivares Alvin Otsuka Eugene Paschold Christopher Sirridge Des Ilegbodu Troy Tuttle Lina Asmar

Lung Cancer 2004 Dec;46(3):369-75

US Oncology Research, Inc., Kansas City Cancer Center, 12200 West 110th Street, Overland Park, KS 66210, USA.

View Article and Find Full Text PDF
December 2004

A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.

Authors:
David M Friedland Shaker Dakhil Charles Hollen Mary Ann Gregurich Lina Asmar

Cancer Invest 2004 ;22(3):374-82

US Oncology, Inc., Houston, Texas, USA.

View Article and Find Full Text PDF
November 2004

Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.

Authors:
William R Berry James W Hathorn Shaker R Dakhil David M Loesch Don V Jackson Mary Ann Gregurich Jennifer K Newcomb-Fernandez Lina Asmar

Clin Prostate Cancer 2004 Sep;3(2):104-11

US Oncology Research, Houston, TX, USA.

View Article and Find Full Text PDF
September 2004

Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.

Authors:
Hemachandra Venkatesh Nicholas Di Bella Thomas P Flynn Mark J Vellek Kristi A Boehm Lina Asmar

Clin Lymphoma 2004 Sep;5(2):110-5

US Oncology Research, Inc., Houston, TX 77090, USA.

View Article and Find Full Text PDF
September 2004

Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.

Authors:
Alan N Gordon Lina Asmar Mark J Messing Daron G Street Charles H Pippitt Cheryl L Bailey John Savage James A Young

Gynecol Oncol 2004 Aug;94(2):533-9

Texas Oncology, P.A., Charles A. Sammons Cancer Center, Dallas, TX 75246, USA.

View Article and Find Full Text PDF
August 2004

Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years.

Authors:
Marcus Neubauer Jonathan Schwartz John Caracandas Paul Conkling Des Ilegbodu Troy Tuttle Lina Asmar

J Clin Oncol 2004 May;22(10):1872-7

Kansas City Cancer Center, Overland Park, KS 66210, USA.

View Article and Find Full Text PDF
May 2004

Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen.

Authors:
Robert Drapkin Nicholas J Di Bella David C Faragher Elizabeth Harden Carmen Matei William Hyman Mae Mirabel Kristi A Boehm Lina Asmar

Clin Lymphoma 2003 Dec;4(3):169-75

US Oncology, Houston, TX, USA.

View Article and Find Full Text PDF
December 2003

Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: a phase II multicenter study.

Authors:
Nicholas J Di Bella Myrna M Khan Shaker R Dakhil Keith W Logie Thomas A Marsland Ralph E Weinstein Mae Y Mirabel Lina Asmar

Clin Lymphoma 2003 Mar;3(4):235-40

US Oncology, Inc., Houston, TX, USA.

View Article and Find Full Text PDF
March 2003

A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.

Authors:
David M Loesch Lina Asmar Vikki A Canfield Gregory A Parker Harry E Hynes Peter G Ellis William A Ferri Nicholas J Robert

Breast Cancer Res Treat 2003 Jan;77(2):115-23

Oncology and Hematology Associates, Inc., Indianapolis, IN 46227-0900, USA.

View Article and Find Full Text PDF
January 2003

Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.

Authors:
William Berry Shaker Dakhil Manuel Modiano Maryann Gregurich Lina Asmar

J Urol 2002 Dec;168(6):2439-43

U.S. Oncology, Houston, Texas, USA.

View Article and Find Full Text PDF
December 2002

Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer.

Authors:
David Loesch Nicholas Robert Lina Asmar Mary Ann Gregurich Mark O'Rourke Shaker Dakhil Edwin Cox

J Clin Oncol 2002 Sep;20(18):3857-64

U.S. Oncology, Inc, Houston, TX, USA.

View Article and Find Full Text PDF
September 2002

Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.

Authors:
Edgardo Rivera Frankie A Holmes Aman U Buzdar Lina Asmar Shu-Wan Kau Giuseppe Fraschini Ronald Walters Richard L Theriault Gabriel N Hortobagyi

Breast J 2002 Jan-Feb;8(1):2-9

Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

View Article and Find Full Text PDF
March 2002